HBM Partners

News from the portfolios of HBM BioVentures and HBM BioCapital


30.6.2008	Basilea's Ceftobiprole, a new anti-MRSA broad-spectrum antibiotic, receives its first marketing authorization by Health Canada
4.6.2008	Ipsen to acquire Tercica
20.5.2008	PharmaSwiss raises EUR 35 million from private equity fund
16.5.2008	Onyx' Nexavar significantly improves overall survival by 47% in Asia-Pacific liver cancer study
16.4.2008	Paratek Pharmaceuticals completes $40 Million private placement to finance clinical programs including oral anti-MRSA antibiotics
16.4.2008	Pelikan Technologies and Lilly form alliance to promote diabetes education
16.4.2008	Newron reports positive Phase II results for ralfinamide in peripheral neuropathic pain patients
7.4.2008	BRAHMS AG: receives FDA clearance to market automated procalcitonin (PCT) test
25.2.2008	ESBATech's antibody fragments demonstrate penetration into the eye with topical delivery via eye drops
29.1.2008	Surface Logix reports phase 2A on SLX-4090

»	Devax receives CE Mark for the AXXESS drug eluting bifurcation stent
»	HBM BioVentures' largest public investment - Micrus - acquired by Johnson & Johnson
»	Lux Biosciences names Dean Mitchell President and CEO
»	Archive